Every Form 4 that Xenon Pharmaceuticals Inc (XENE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow XENE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XENE filings page.
Xenon Pharmaceuticals Inc. (XENE) director Dawn Svoronos exercised stock options for 5,144 Common Shares on September 1, 2026 at an exercise price of $8.15 per share, converting fully vested options into shares. Following the exercise, she holds 31,373 Common Shares directly, and no related Rule 10b5-1 trading plan is reported.
Xenon Pharmaceuticals Inc. (XENE) reported that Chief Medical Officer Christopher John Kenney sold a total of 7,068 Common Shares on August 28, 2026 in two open-market transactions, executed under a Rule 10b5-1 trading plan adopted on May 29, 2026. The reported prices are weighted-average prices for multiple trades within specified intraday ranges.
Xenon Pharmaceuticals Inc. director Steven Gannon reported selling 10,000 Common Shares on August 11, 2026 in an open market or private transaction. The shares were sold at a weighted-average price of $64.055 across multiple trades priced between $64.0517 and $64.078 per share. Following this sale, Gannon directly holds 1,870 Common Shares of Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals director Gary Patou reported an open-market sale of 1,322 Common Shares of Xenon Pharmaceuticals Inc. at $53.14 per share on June 5, 2026. After this transaction, he directly holds 24,896 Common Shares and has an additional 4,902 Common Shares held indirectly.
The filing notes that the sales were effected under a Rule 10b5-1 trading plan adopted on August 17, 2025, established solely to cover income tax obligations related to the vesting of restricted stock units granted on June 5, 2025. This indicates the sale was pre-planned and tied to tax liabilities rather than a discretionary trade.
Xenon Pharmaceuticals Inc. director Gillian Cannon reported an open-market sale of common shares. On June 5, 2026, she sold 1,190 Common Shares at an average price of $53.14 per share and now directly holds 1,455 shares.
According to a footnote, these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on August 15, 2025, and were executed solely to cover income tax obligations arising from the vesting of RSUs granted on June 5, 2025.
PATOU GARY reported acquisition or exercise transactions in this Form 4 filing.
Xenon Pharmaceuticals director Gary Patou reported several equity compensation moves. He received a grant of 1,593 restricted share units (RSUs) and a separate grant of 10,507 share options with a strike price of $53.4600 per share expiring on June 2, 2036. Earlier, on June 1, 2026, 2,645 RSUs from a prior award vested 100% and were settled into the same number of common shares, lifting his direct common share holdings to 26,218 shares. The filing also shows 4,902 common shares held indirectly through the Gary & Karen Barbara Patou trustees of the Patou Family Trust.
Xenon Pharmaceuticals Inc. director Patrick Machado reported multiple equity awards and an option exercise. On June 1, 2026, 2,645 Restricted Share Units (RSUs) vested, converting into 2,645 Common Shares, all held directly. On June 3, 2026, he received 1,593 additional RSUs and an option grant for 10,507 shares with a $53.4600 exercise price, expiring on June 2, 2036. The newly granted RSUs and options are scheduled to vest or become exercisable in connection with the issuer’s 2027 annual meeting of shareholders.
Xenon Pharmaceuticals director Justin D. Gover reported equity compensation and an option exercise. He exercised 2,645 Restricted Share Units into 2,645 Common Shares on June 1, 2026, reflecting a 100% vesting of an RSU award originally granted on June 5, 2025.
On June 3, 2026, he received 1,593 Restricted Share Units and a Share Option for 10,507 Common Shares at an exercise price of $53.4600 per share, expiring on June 2, 2036. Both the new RSUs and the option vest 100% on the earlier of June 1, 2027 or the day before Xenon’s 2027 annual meeting of shareholders.
Xenon Pharmaceuticals director Elizabeth A. Garofalo reported compensation-related equity transactions with no open-market buying or selling. On June 1, 2026, 2,645 Restricted Share Units vested and were exercised into 2,645 Common Shares, fully settling that RSU award. On June 3, 2026, she received 1,593 new Restricted Share Units and an option to purchase 10,507 Common Shares at an exercise price of $53.4600 per share, both vesting 100% on the earlier of June 1, 2027 or the day before the 2027 annual meeting of shareholders.
Xenon Pharmaceuticals director Steven Gannon reported routine equity compensation and related share movements. He received 1,593 restricted share units (RSUs) that each entitle him to one common share, vesting 100% on the earlier of June 1, 2027 or the day before the 2027 annual shareholder meeting. He was also granted options to buy 10,507 common shares at an exercise price of $53.46 per share, expiring in 2036. Separately, 2,645 RSUs granted in 2025 fully vested on June 1, 2026 and were settled into the same number of common shares; 1,416 of those shares were withheld by the company at a price of $53.41 per share to cover tax obligations, which the company notes does not represent a sale. After these transactions, Gannon directly holds 11,870 common shares.
Xenon Pharmaceuticals Inc. director Gillian Cannon reported routine equity compensation and an option exercise. She received 1,593 Restricted Share Units and 10,507 share options with an exercise price of $53.4600 per share, each tied to future vesting. Separately, 2,645 RSUs granted on June 5, 2025 fully vested on June 1, 2026 and were settled into an equal number of common shares. The new RSU grant and options vest 100% on the earlier of June 1, 2027 or the day before the company’s 2027 annual meeting of shareholders.
Xenon Pharmaceuticals director Dawn Svoronos reported routine equity compensation activity. Previously granted restricted share units vested into 2,645 Common Shares, and the company withheld 1,416 shares at $53.41 to cover income taxes, which the filing notes does not represent a sale.
Following these transactions, she directly holds 26,229 Common Shares. On the same date, she received new awards of 1,593 restricted share units and options for 10,507 shares with a $53.46 exercise price expiring on June 2, 2036, both vesting in full around the issuer’s 2027 annual meeting of shareholders.
Xenon Pharmaceuticals Inc. director Steven Gannon exercised stock options to acquire 3,500 Common Shares at an exercise price of $7.38 per share. This exercise-and-hold transaction increased his directly held stake to 10,641 Common Shares following the transaction. The underlying stock options were fully vested and exercisable and, after this exercise, no related options in this grant remain outstanding.
Xenon Pharmaceuticals Inc. Chief Medical Officer Christopher John Kenney reported routine equity compensation activity and a small open-market sale. On March 12, 2026, he exercised 3,750 Restricted Share Units at $0.00 per share, converting them into 3,750 Common Shares that had vested from a grant made on March 12, 2025.
The RSU award vests in four equal annual installments starting on March 12, 2026, and after this vesting he held 11,250 Restricted Share Units directly. On March 13, 2026, he sold 1,410 Common Shares at an average price of $55.225 per share under a Rule 10b5-1 durable sell-to-cover instruction adopted on December 3, 2025, solely to satisfy tax withholding obligations related to the RSU vesting. Following these transactions, he directly owned 7,069 Common Shares.
Xenon Pharmaceuticals Inc.’s Chief Legal Officer, Andrea DiFabio, reported routine equity compensation activity. On March 12, 2026, 3,750 restricted share units granted on March 12, 2025 vested and were converted into an equal number of common shares at no cost. On March 13, 2026, 1,342 common shares were sold at $55.225 per share pursuant to a pre-arranged Rule 10b5-1 “sell-to-cover” instruction used solely to satisfy tax withholding on the RSU vesting. After these transactions, DiFabio holds 7,301 common shares directly and 11,250 RSUs remain outstanding under the award, vesting in equal annual installments over four years beginning March 12, 2026.
Xenon Pharmaceuticals Inc. President & CEO Ian Mortimer reported a combination of equity compensation and a small share sale. On March 12, 2026, RSUs covering 12,500 Common Shares vested and were exercised at $0, increasing his direct shareholdings. On March 13, 2026, he executed an open-market sale of 7,308 Common Shares at $55.225 per share under a pre-arranged Rule 10b5-1 “sell-to-cover” instruction adopted on December 3, 2025, solely to satisfy tax withholding tied to the RSU vesting. Following these transactions, Mortimer holds 19,923 Common Shares directly and 14,300 Common Shares indirectly through his spouse, along with 37,500 Restricted Share Units that remain outstanding.
Xenon Pharmaceuticals Inc. reported that Chief Medical Officer Christopher John Kenney had performance share units (PSUs) granted on March 11, 2024 vest after the board determined milestone achievement. These PSUs, totaling 7,500 units, immediately converted into 7,500 common shares.
Following this vesting, Kenney sold 2,771 common shares on March 10, 2026 at an average price of $60.108 per share under a Rule 10b5-1 durable sell-to-cover instruction adopted on December 3, 2025 solely to satisfy tax withholding obligations related to the PSU vesting. After these transactions, he directly holds 4,729 common shares.
Xenon Pharmaceuticals Inc. Chief Legal Officer Andrea DiFabio reported equity compensation vesting and a related share sale. On March 9, 2026, 7,500 Performance Share Units vested based on the Board’s milestone assessment and were converted into 7,500 Common Shares at $0.00 per share.
On March 10, 2026, DiFabio sold 2,607 Common Shares in an open‑market transaction at an average price of $60.108 per share under a pre‑arranged Rule 10b5‑1 sell‑to‑cover instruction to satisfy tax withholding on the PSU vesting, leaving 4,893 Common Shares held directly.
Xenon Pharmaceuticals Inc. President & CEO Ian Mortimer reported a combination of option exercises, performance share vesting and share sales. He exercised stock options covering 290,000 Common Shares at exercise prices between $3.10 and $9.44 per share, and a 20,000-unit performance share award vested based on milestone achievement.
Across multiple open-market transactions, he sold a total of 281,269 Common Shares at weighted-average prices generally between the high-$50s and low-$60s. Footnotes state these sales were made under Rule 10b5‑1 trading arrangements, including a durable sell-to-cover instruction adopted solely to satisfy tax withholding on the vested performance share units. After these transactions, he holds 14,731 Common Shares directly and 14,300 Common Shares indirectly through his spouse.
Xenon Pharmaceuticals Inc. reported a new equity award for its Chief Medical Officer, Christopher John Kenney. On January 9, 2026, he received a share option covering 100,000 common shares with an exercise price of $42.15 per share. This option vests 25% on January 9, 2027, with the remaining 75% vesting in equal monthly installments over the next three years, encouraging longer-term retention.
On the same date, he was also granted 20,000 restricted share units, each representing a right to receive one common share. These RSUs vest in four equal 25% installments on each of the first four anniversaries of the grant date, beginning January 9, 2027. Both awards are reported as directly owned and reflect equity-based compensation rather than any sale of existing shares.
Xenon Pharmaceuticals Inc. reported new equity awards to its Chief Commercial Officer, Darren S. Cline. On January 9, 2026, he received a share option for 40,000 common shares with an exercise price of $42.15 per share, all held directly. This option vests 25% on January 9, 2027, with the remaining 75% vesting in equal monthly amounts over the following three years.
On the same date, he was also awarded 20,000 restricted share units, each representing a contingent right to receive one common share. These RSUs vest in four equal installments of 25% on each of the first four anniversaries of the grant date, beginning on January 9, 2027. Both awards are reported as directly owned derivative securities following the transactions.
Xenon Pharmaceuticals Inc. Chief Legal Officer Andrea DiFabio reported new equity awards. On January 9, 2026, DiFabio received share options covering 80,000 common shares at an exercise price of $42.15 per share, with no purchase price for the grant itself. These options vest 25% on January 9, 2027, with the remaining 75% vesting in equal monthly installments over the following three years.
On the same date, DiFabio was also granted 15,000 restricted share units, each representing a contingent right to receive one common share. These RSUs vest 25% on each of the first four anniversaries of the grant date, beginning January 9, 2027. Both awards are reported as directly held derivative securities.
Xenon Pharmaceuticals Inc. President & CEO Ian Mortimer reported new equity awards. On January 9, 2026, he received a stock option for 350,000 common shares at an exercise price of $42.15 per share. This option vests 25% on January 9, 2027, with the remaining 75% vesting in equal monthly installments over the following three years.
He also received 65,000 restricted share units, each representing a contingent right to receive one common share. These restricted share units vest 25% on each of the first four anniversaries of the grant date, beginning January 9, 2027. Both the option and the restricted share units are reported as directly owned.
Xenon Pharmaceuticals Inc.’s president and CEO, who is also a director, reported open-market sales of company common shares under a Rule 10b5-1 trading plan. On 12/05/2025 the insider sold 14,375 common shares at a weighted-average price of $45.03 per share. On 12/08/2025 additional trades involved 8,820 shares at a weighted-average $45.59 and 2,010 shares at a weighted-average $46.32, each executed in multiple transactions within stated price ranges. Following these sales, the insider beneficially owns 6,000 common shares directly and 14,300 common shares indirectly through a spouse; the Rule 10b5-1 trading plan was adopted on September 27, 2024.
Xenon Pharmaceuticals (XENE) filed a Form 4 reporting new equity awards to its Chief Financial Officer. On 10/15/2025, the officer received a stock option for 225,000 common shares at an exercise price of $41.9, expiring on 10/14/2035. The option vests 25% on October 15, 2026, with the remaining 75% vesting in equal monthly installments over the next three years.
The filing also reports 30,000 restricted share units (RSUs), vesting 25% on each of the first four anniversaries of the grant date, beginning October 15, 2026. The awards are reported as direct ownership.
Xenon Pharmaceuticals insider transactions by Ian Mortimer show the reporting person exercised a fully vested option to buy 25,000 common shares at $7.69 and simultaneously sold 25,000 shares under a prearranged Rule 10b5-1 plan on 10/01/2025. The sale proceeds reflect an aggregate weighted-average price of $40.16 per share (individual sales ranged $40.00 to $40.495). After these transactions Mortimer directly beneficially owned 31,302 shares and indirectly owned 14,300 shares through his spouse, totaling 45,602 shares. The filing states the option exercised is fully vested and exercisable and that the sales were executed under a 10b5-1 plan.